WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 517

Legislative bill overview

SB 517 addresses pricing transparency and regulatory requirements for entities participating in the 340B drug pricing program, a federal initiative that allows eligible healthcare organizations to purchase medications at discounted rates. The bill appears designed to establish fair pricing standards and transparency measures for covered entities—hospitals, clinics, and other providers—that benefit from these discounts.

Why is this important

The 340B program significantly impacts drug costs for vulnerable patient populations served by safety-net hospitals and community health centers. Transparency and pricing fairness measures could affect how discounted medications are distributed, potentially influencing drug availability and costs for uninsured and underinsured patients, while also impacting pharmaceutical manufacturer practices and provider profit margins.

Potential points of contention

  • Federal vs. state authority: The 340B program is federally regulated; North Carolina's attempt to impose additional state-level requirements could create legal and compliance conflicts with federal law and regulations
  • Industry opposition: Pharmaceutical manufacturers and some covered entities may resist transparency requirements if they increase administrative burden or reduce profit incentives
  • Implementation costs: Healthcare providers may argue that new compliance and reporting requirements impose unfunded mandates that strain already tight budgets

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.